Malcolm Gates is our Vice President of Finance, with oversight of all financial matters. Prior to joining Alchemab, Malcolm was most recently Vice President of Finance at Evonetix, a venture capital backed research company in Cambridge. Prior to that Malcolm was Group Finance Director at Cambridge Cognition, an AIM listed public company, for six years. […]

Alex Hewitson is our Chief Operating Officer, where he has global oversight of our operations footprint and our human resources function. Prior to joining Alchemab, Alex held several senior leadership roles within AstraZeneca where he was most recently Head of Operations, ensuring business operations were maintained during the company’s transitional move to Cambridge, leading the […]

Paul Varley is our Chief Development Officer where he oversees our development processes including Pre-clinical Development, Toxicology, Chemistry Manufacturing and Control (CMC) and Quality. Prior to joining Alchemab, Paul held similar roles at Kymab, Ltd., AstraZeneca/MedImmune and Cambridge Antibody Technology. Paul also worked at British Biotech, the UK National Institute of Biological Standards and Control […]

Jake Galson is Alchemab’s Vice President of Technology where he leads the development and application of novel technologies for the company.  Prior to Alchemab, Jake was the Bioinformatics lead at Kymab Ltd, where his group developed the IntelliSelect® antibody discovery software platform. Jake is also one of the pioneers of immune receptor repertoire sequencing, serving […]

Ralph Minter is our Chief Scientific Officer and leads our antibody discovery efforts. Prior to joining Alchemab, Ralph was Senior Director in Antibody Discovery and Protein Engineering at AstraZeneca where he led discovery teams and developed candidate drugs across multiple disease areas. Before joining AstraZeneca, he was part of Cambridge Antibody Technology (CAT), which later […]